Transcranial Magnetic Stimulation (TMS) Effects Using Magnetoencephalography (MEG) Study

Part of paid clinical trials in Winston-Salem, North Carolina.

Sponsor
Wake Forest University Health Sciences
Study ID
NCT06770556
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
21 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • Sham iTBS — DEVICE
    Participants will receive sham iTBS
  • Active iTBS — DEVICE
    Participants will receive active iTBS
  • 10 Hz TMS — DEVICE
    Participant will receive 10 Hz TMS
  • 1 Hz TMS — DEVICE
    Participant will receive 1 Hz TMS

Study Details

Alcohol use disorder (AUD) is a complex chronic brain disease characterized by compulsive alcohol use, loss of control over drinking, and negative emotional states. Extensive research has identified the general neural circuitry underlying AUD. There is an exciting opportunity to intervene in AUD using neuromodulation. Transcranial magnetic stimulation (TMS) offers a non-invasive method to modulate brain activity, making it a promising tool for investigating, modulating, and potentially treating AUD. However, the precise effects of TMS on neural circuits involved in AUD and the mechanisms underlying these effects must first be understood. Magnetoencephalography (MEG) is a neuroimaging method that provides direct measurement of brain activity within neural circuits with high temporal resolution. Critically, MEG can measure brain activity in a wide range of frequencies that are consistent with those targeted by TMS. The goal of this proposal is therefore to collect preliminary and feasibility data to support a future NIH grant application that would use MEG to investigate TMS effects in individuals with AUD (iAUD).

Key Dates

Start date
Mar 21, 2025
Status verified
Feb 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
10 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE

Arms

  • Other: Four Day - Option 1
    Participants will receive active iTBS, sham iTBS, 10 Hz, 1 Hz.
  • Other: Two Day - Option 1
    Participants will receive active iTBS then sham iTBS.
  • Other: Four Day - Option 2
    Participants will receive sham iTBS, active iTBS, 1 Hz, 10 Hz.
  • Other: Two Day - Option 2
    Participants will receive sham iTBS then active iTBS.

Primary Outcome Measure

Number of Adverse Events Potentially Related to TMS [ Time Frame: Through study completion 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Wake Forest University Health SciencesWinston-SalemNorth Carolina27157
Merideth A Addicott, PhD
[email protected]
336-716-7792

Find similar trials in Winston-Salem, NC

By condition
Substance use disorder
By specialty
Behavioral healthAddiction medicine
By research site
Wake Forest University Health Sciences· Winston-Salem, NC

Related Studies